Keyphrases
T Cells
100%
Allogeneic
100%
Graft-versus-host Disease (GvHD)
100%
Long-term Survival
100%
Myeloma
100%
Allogeneic T Cells
100%
Multiple Myeloma
83%
Adoptive Cell Therapy
83%
Tumor
33%
Autoreactive T Cells
33%
Bone Marrow Transplantation
33%
Myeloma Cells
33%
Therapy Protocols
33%
Donor T Cell
33%
Graft-versus-myeloma
33%
Reactive Donors
33%
Transplantation
16%
Nave
16%
Mouse Model
16%
Murine Model
16%
Interleukin-2
16%
Therapy Strategy
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Improved Survival
16%
Anti-CD28
16%
T Cell Receptor
16%
Induction Therapy
16%
Prestimulus
16%
Multiple Myeloma Patients
16%
Repeated Infusions
16%
Anti-CD3/CD28
16%
Total Body Irradiation
16%
Allogeneic Bone Marrow Transplantation
16%
Reactive Lymphadenopathy
16%
Medicine and Dentistry
T Cell
100%
Infusion
100%
Myeloma
100%
Long Term Survival
100%
Graft Versus Host Reaction
100%
Multiple Myeloma
72%
Cell Therapy
45%
Neoplasm
18%
Myeloma Cell
18%
Symptom
9%
Disease
9%
Immunotherapy
9%
Ex Vivo
9%
Lymphocyte
9%
Bone Marrow Transplantation
9%
T Lymphocyte Receptor
9%
Induction Chemotherapy
9%
Autologous Bone Marrow Transplantation
9%
Allogenic Bone Marrow Transplantation
9%
Autologous Stem Cell Transplantation
9%
Whole Body Radiation
9%
Immunology and Microbiology
T Cell
100%
Long Term Survival
100%
Graft-Versus-Host Disease
100%
Multiple Myeloma
72%
Bone Marrow Transplantation
18%
Myeloma Cell
18%
Mouse
9%
Mouse Model
9%
Immunotherapy
9%
CD3 Antigen
9%
CD28
9%
T Cell Receptor
9%
Autologous Stem Cell Transplantation
9%
Reactive Lymphocyte
9%
Allogeneic Bone Marrow Transplantation
9%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Long Term Survival
100%
Host
100%
Mouse
9%
Mouse Model
9%
T Cell Receptor
9%
Reactive Lymphocyte
9%
CD28
9%
Autologous Stem Cell Transplantation
9%